In last trading session, Aligos Therapeutics Inc (NASDAQ:ALGS) saw 0.47 million shares changing hands with its beta currently measuring 2.51. Company’s recent per share price level of $39.84 trading at $1.49 or 3.89% at ring of the bell on the day assigns it a market valuation of $142.95M. That closing price of ALGS’s stock is at a premium of 1.36% from its 52-week high price of $39.30 and is indicating a premium of 83.03% from its 52-week low price of $6.76. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.45 million shares which gives us an average trading volume of 342.98K if we extend that period to 3-months.
For Aligos Therapeutics Inc (ALGS), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 9 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -3.67 in the current quarter.
Aligos Therapeutics Inc (NASDAQ:ALGS) trade information
Upright in the green during last session for gaining 3.89%, in the last five days ALGS remained trading in the green while hitting it’s week-highest on Friday, 12/20/24 when the stock touched $39.84 price level, adding 4.32% to its value on the day. Aligos Therapeutics Inc’s shares saw a change of 140.00% in year-to-date performance and have moved 16.94% in past 5-day. Aligos Therapeutics Inc (NASDAQ:ALGS) showed a performance of 118.90% in past 30-days. Number of shares sold short was 0.28 million shares which calculate 0.5 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 3 to the stock, which implies a fall of -1228.0% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 3. It follows that stock’s current price would jump 92.47% in reaching the projected high whereas dropping to the targeted low would mean a gain of 92.47% for stock’s current value.
Aligos Therapeutics Inc (ALGS) estimates and forecasts
Statistics highlight that Aligos Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 271.47% of value to its shares in past 6 months, showing an annual growth rate of 69.53% while that of industry is 17.40. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -59.91% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 433.33k for the same. And 3 analysts are in estimates of company making revenue of 333.33k in the next quarter. Company posted 2.01M and 986k of sales in current and next quarters respectively a year earlier.
Aligos Therapeutics Inc (NASDAQ:ALGS)’s Major holders
Insiders are in possession of 17.80% of company’s total shares while institution are holding 48.86 percent of that, with stock having share float percentage of 59.44%. Investors also watch the number of corporate investors in a company very closely, which is 48.86% institutions for Aligos Therapeutics Inc that are currently holding shares of the company. ARMISTICE CAPITAL, LLC is the top institutional holder at ALGS for having 7.26 million shares of worth $2.54 million. And as of 2024-06-30, it was holding 4.6471 of the company’s outstanding shares.
The second largest institutional holder is ECOR1 CAPITAL, LLC, which was holding about 6.39 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.0919 of outstanding shares, having a total worth of $2.24 million.
